Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Jaguar Health (JAGX) Shares Outstanding (Weighted Average) (2016 - 2025)

Jaguar Health (JAGX) has disclosed Shares Outstanding (Weighted Average) for 11 consecutive years, with $2.3 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 691.9% to $2.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.3 million through Dec 2025, up 691.9% year-over-year, with the annual reading at $2.3 million for FY2025, 691.9% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $2.3 million at Jaguar Health, down from $2.6 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $45.8 million in Q3 2021, with the low at $5.0 in Q4 2022.
  • Average Shares Outstanding (Weighted Average) over 5 years is $7.6 million, with a median of $852776.0 recorded in 2022.
  • The sharpest move saw Shares Outstanding (Weighted Average) crashed 99.93% in 2022, then soared 161360.0% in 2023.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $7513.0 in 2021, then plummeted by 99.93% to $5.0 in 2022, then skyrocketed by 161360.0% to $8073.0 in 2023, then soared by 3548.38% to $294534.0 in 2024, then surged by 691.9% to $2.3 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $2.3 million, $2.6 million, and $2.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.